Crescendo Biologics Evolves in Immuno-Oncology Under New Management
This article was originally published in Scrip
First convinced as an investor by flourishing technology at Crescendo Biologics, Peter Pack has since been wooed to take up the position of CEO at the company. In a recent interview Pack told Scrip of his plans for transforming the firm from a resourceful technology platform business to a fully fledged oncology drug discovery company.
Register for our free email digests: